Inspire Advisors LLC Purchases 133 Shares of IDEXX Laboratories, Inc. $IDXX

Inspire Advisors LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,488 shares of the company’s stock after buying an additional 133 shares during the period. Inspire Advisors LLC’s holdings in IDEXX Laboratories were worth $798,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of IDXX. Bank of New York Mellon Corp boosted its position in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after acquiring an additional 884,808 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares during the last quarter. Generation Investment Management LLP bought a new stake in shares of IDEXX Laboratories in the second quarter worth $304,277,000. Select Equity Group L.P. acquired a new position in IDEXX Laboratories during the first quarter worth $194,834,000. Finally, Nuveen LLC acquired a new position in IDEXX Laboratories during the first quarter worth $179,784,000. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. The trade was a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 0.2%

Shares of IDXX stock opened at $670.21 on Wednesday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $735.00. The stock has a market cap of $53.52 billion, a price-to-earnings ratio of 55.80, a PEG ratio of 4.06 and a beta of 1.62. The firm’s 50-day moving average is $652.36 and its 200-day moving average is $592.66. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $2.80 EPS. The firm’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on IDXX. UBS Group lifted their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Sunday. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, BTIG Research boosted their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.